Key result
Transcoronary gradients for BNP, Gal-3, and TIMP-1 indicate intracardiac production in heart failure.
Why the study?
Biomarkers are pivotal in heart failure management, but their lack of cardiac specificity could limit clinical utility.
Are there transcoronary gradients and intracardiac production of novel biomarkers in patients with heart failure?
Observational (n=40)
Are there transcoronary gradients and intracardiac production of novel biomarkers in patients with heart failure?
BNP, Gal-3, and TIMP-1 show significant transcoronary gradients in heart failure patients, indicating intracardiac production.
Answers are grounded in this paper and cite their sources.
Supports intracardiac production of Gal-3 and TIMP-1 in HF; hypothesis-generating for monitoring beyond BNP.
AIMS: Biomarkers are pivotal in the management of heart failure (HF); however, their lack of cardiac specificity could limit clinical utility. This study aimed to investigate the transcoronary changes and intracardiac production of these biomarkers. METHODS: Transcoronary gradients for B-type natriuretic peptide (BNP) and five novel biomarkers-galectin-3 (Gal-3), soluble suppression of tumourigenicity 2 (sST2), tissue inhibitor of metalloproteinase 1 (TIMP-1), growth differentiation factor 15 (GDF-15) and myeloperoxidase (MPO)-were determined using femoral artery (FA) and coronary sinus (CS) samples from 30 HF patients and 10 non-HF controls. Intracardiac biomarker production was assessed in an HF canine model using real-time quantitative PCR (qPCR) and western blot (WB) analysis. RESULTS: Compared with the control group, levels of all detected biomarkers were significantly elevated in the HF group, while transcoronary gradients were only observed for BNP, Gal-3 and TIMP-1 levels in the HF group (BNP: FA: 841.5 ± 727.2 ng/mL vs. CS: 1132.0 ± 959.1 ng/mL, P = 0.005; Gal-3: FA: 9.5 ± 3.0 ng/mL vs. CS: 19.7 ± 16.4 ng/mL, P = 0.002; and TIMP-1: FA: 286.7 ± 68.9 ng/mL vs. CS: 377.3 ± 108.9 ng/mL, P = 0.001). Real-time qPCR and WB analysis revealed significant elevation of BNP, Gal-3 and TIMP-1 in the cardiac tissues of the HF group relative to other groups. CONCLUSIONS: This study provided evidence of transcoronary changes in BNP, Gal-3 and TIMP-1 levels in HF patients, offering insights into their intracardiac production. These findings enhance the understanding of the biology of these biomarkers and may inform their clinical application.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2024) conducted an observational in Heart Failure (n=40). Biomarker transcoronary gradient assessment vs. Non-HF controls was evaluated on Transcoronary gradients for BNP, Gal-3, sST2, TIMP-1, GDF-15, and MPO. Significant transcoronary gradients were observed in heart failure patients for BNP, Gal-3, and TIMP-1, indicating intracardiac production of these biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: